The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Ixekizumab Promising for AS; Plus Certolizumab Pegol Studied for Psoriasis

Ixekizumab Promising for AS; Plus Certolizumab Pegol Studied for Psoriasis

March 14, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In the latest Phase 3 study of ixekizumab, it proved safe and effective to treat adults with ankylosing spondylitis (AS). Plus, data from three Phase 3 studies demonstrate certolizumab pegol’s potential to treat adults with psoriasis.

You Might Also Like
  • Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial
  • Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis
  • Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol
Explore This Issue
April 2018
Also By This Author
  • Improving Bone Mineral Density: Risedronate vs. Denosumab

Ixekizumab Efficacious & Safe for AS
In a Phase 3 study, ixekizumab (Taltz) met primary and key secondary endpoints for safety and efficacy to treat AS, or radiographic axial spondyloarthritis (axSpA).1 This trial, known as COAST-V, was placebo controlled, included an active control arm with patients taking adalimumab and evaluated patients who were biologic disease-modifying anti-rheumatic drug (bDMARD) naive.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the COAST-V study, statistically significant improvements in AS signs and symptoms were seen in the ixekizumab-treated patients. Signs and symptoms were measured by the proportion of patients who achieved Assessment of Spondyloarthritis International Society (ASAS) 40 response at Week 16 compared with placebo-treated patients. The ASAS40 was used to measure the primary endpoint, rather than the ASAS 20, which is the most commonly used standard endpoint in AS clinical trials.

During the trial, no new safety signals were noted. Additionally, the most common adverse events were consistent with adverse events that occurred during Phase 3 clinical trials that investigated ixekizumab for use in patients with active psoriatic arthritis and moderate to severe plaque psoriasis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At present, ixekizumab is approved by the U.S. Food and Drug Administration to treat adults with active psoriatic arthritis or moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Certolizumab Pegol & Psoriasis
Three pooled subanalyses from the ongoing, Phase 3 studies CIMPASI-1, CIMPASI-2 and CIMPACT highlight the potential versatility of certolizumab pegol for treating psoriasis. The findings were presented at the American Academy of Dermatology Annual Meeting in February.2

Study patients were randomized into three groups to receive 400 mg certolizumab pegol every two weeks (n=342), 200 mg certolizumab pegol every two weeks after a 400 mg loading dose at Weeks 0, 2 and 4 (n=351) or placebo every two weeks (n=157). The patients were 18 years of age or older, who had a diagnosis of moderate to severe psoriasis for at least six months, a PASI of at least 12 and at least 10% of their body surface area affected. Patients also had to have a physician’s global assessment (PGA) [5-point scale] of at least three with no prior certolizumab pegol (or etanercept in CIMPACT) use or no more than two biologics previously used.3

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates, Spondyloarthritis Tagged With: Ankylosing Spondylitis, Certolizumab Pegol, ixekizumab, PsoriasisIssue: April 2018

You Might Also Like:
  • Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial
  • Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis
  • Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol
  • FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)